AAPM Task Group Report 307: Use of EPIDs for Patient-Specific IMRT and VMAT QA

被引:0
作者
Dogan N. [1 ]
Mijnheer B.J. [2 ]
Padgett K. [1 ]
Nalichowski A. [3 ]
Wu C. [4 ]
Nyflot M.J. [5 ]
Olch A.J. [6 ]
Papanikolaou N. [7 ]
Shi J. [8 ]
Holmes S.M. [9 ]
Moran J. [10 ]
Greer P.B. [11 ,12 ]
机构
[1] Department of Radiation Oncology, University of Miami Miller School of Medicine, Miami, FL
[2] Department of Radiation Oncology, Netherlands Cancer Institute, Amsterdam
[3] Department of Radiation Oncology, Karmanos Cancer Institute, Detroit, MI
[4] Department of Radiation Oncology, Sutter Medical Foundation, Roseville, CA
[5] Department of Radiation Oncology, University of Washington, Seattle, WA
[6] Department of Radiation Oncology, University of Southern California, and Children's Hospital Los Angeles, Los Angeles, CA
[7] Division of Medical Physics, UT Health-MD Anderson, San Antonio, TX
[8] Sun Nuclear Corporation – A Mirion Medical Company, Melbourne, FL
[9] Standard Imaging, Inc., Middleton, WI
[10] Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY
[11] Department of Radiation Oncology, Calvary Mater Newcastle Hospital, Newcastle, NSW
[12] School of Information and Physical Sciences, University of Newcastle, Newcastle, NSW
关键词
electronic portal imaging device; EPID; EPID QA; IMRT/VMAT QA; patient-specific EPID QA;
D O I
10.1002/mp.16536
中图分类号
学科分类号
摘要
Purpose: Electronic portal imaging devices (EPIDs) have been widely utilized for patient-specific quality assurance (PSQA) and their use for transit dosimetry applications is emerging. Yet there are no specific guidelines on the potential uses, limitations, and correct utilization of EPIDs for these purposes. The American Association of Physicists in Medicine (AAPM) Task Group 307 (TG-307) provides a comprehensive review of the physics, modeling, algorithms and clinical experience with EPID-based pre-treatment and transit dosimetry techniques. This review also includes the limitations and challenges in the clinical implementation of EPIDs, including recommendations for commissioning, calibration and validation, routine QA, tolerance levels for gamma analysis and risk-based analysis. Methods: Characteristics of the currently available EPID systems and EPID-based PSQA techniques are reviewed. The details of the physics, modeling, and algorithms for both pre-treatment and transit dosimetry methods are discussed, including clinical experience with different EPID dosimetry systems. Commissioning, calibration, and validation, tolerance levels and recommended tests, are reviewed, and analyzed. Risk-based analysis for EPID dosimetry is also addressed. Results: Clinical experience, commissioning methods and tolerances for EPID-based PSQA system are described for pre-treatment and transit dosimetry applications. The sensitivity, specificity, and clinical results for EPID dosimetry techniques are presented as well as examples of patient-related and machine-related error detection by these dosimetry solutions. Limitations and challenges in clinical implementation of EPIDs for dosimetric purposes are discussed and acceptance and rejection criteria are outlined. Potential causes of and evaluations of pre-treatment and transit dosimetry failures are discussed. Guidelines and recommendations developed in this report are based on the extensive published data on EPID QA along with the clinical experience of the TG-307 members. Conclusion: TG-307 focused on the commercially available EPID-based dosimetric tools and provides guidance for medical physicists in the clinical implementation of EPID-based patient-specific pre-treatment and transit dosimetry QA solutions including intensity modulated radiation therapy (IMRT) and volumetric modulated arc therapy (VMAT) treatments. © 2023 The Authors. Medical Physics published by Wiley Periodicals LLC on behalf of American Association of Physicists in Medicine.
引用
收藏
页码:e865 / e903
页数:38
相关论文
共 151 条
[1]  
Antonuk L.E., Boudry J., Huang W.D., Et al., Demonstration of megavoltage and diagnostic-x-ray imaging with hydrogenated amorphous-silicon arrays, Med Phys, 19, pp. 1455-1466, (1993)
[2]  
Antonuk L.E., Yorkston J., Huang W.D., Sandler H., Siewerdsen J.H., ElMohri Y., Megavoltage imaging with a large-area, flat-panel, amorphous silicon imager, Int J Radiat Oncol Biol Phys, 36, pp. 661-672, (1996)
[3]  
Herman M.G., Balter J.M., Jaffray D.A., Et al., Clinical use of electronic portal imaging: report of AAPM Radiation Therapy Committee Task Group 58, Med Phys, 28, pp. 712-737, (2001)
[4]  
Luchka K., Chen D., Shalev S., Gluhchev G., Rajapakshe R., Assessing radiation and light field congruence with a video based electronic portal imaging device, Med Phys, 23, pp. 1245-1252, (1996)
[5]  
Essers M., Boellaard R., vanHerk M., Lanson H., Mijnheer B., Transmission dosimetry with a liquid-filled electronic portal imaging device, Int J Radiat Oncol Biol Phys, 34, pp. 931-941, (1996)
[6]  
Kirby M.C., Williams P.C., The use of an electronic portal imaging device for exit dosimetry and quality-control measurements, Int J Radiat Oncol Biol Phys, 31, pp. 593-603, (1995)
[7]  
Masi L., Casamassima F., Doro R., Francescon P., Quality assurance of volumetric modulated arc therapy: evaluation and comparison of different dosimetric systems, Med Phys, 38, pp. 612-621, (2011)
[8]  
Hussein M., Adams E.J., Jordan T.J., Clark C.H., Nisbet A., A critical evaluation of the PTW 2D-ARRAY seven29 and OCTAVIUS II phantom for IMRT and VMAT verification, J Appl Clin Med Phys, 14, 6, pp. 274-292, (2013)
[9]  
Son J., Baek T., Lee B., Et al., A comparison of the quality assurance of four dosimetric tools for intensity modulated radiation therapy, Radiol Oncol, 49, pp. 307-313, (2015)
[10]  
Colodro J.F.M., Berna A.S., Puchades V.P., Amores D.R., Banos M.A., Volumetric-modulated arc therapy lung stereotactic body radiation therapy dosimetric quality assurance: a comparison between radiochromic film and chamber array, J Med Phys, 42, pp. 133-139, (2017)